What is the projected CAGR for the Dyslipidemia Drugs Market?

The Dyslipidemia Drugs Market is expected to expand at a healthy CAGR of 3.5% from 2019 to 2027.

Which segment is expected to dominate the Dyslipidemia Drugs Market?

The statins segment is anticipated to dominate the Dyslipidemia Drugs Market.

How is the COVID-19 pandemic impacting the Dyslipidemia Drugs Market?

The article provides an analysis of the COVID-19 impact on the Dyslipidemia Drugs Market, indicating significant changes in market dynamics.

What regions are expected to see significant growth in the Dyslipidemia Drugs Market?

The Asia Pacific market is projected to expand significantly in the Dyslipidemia Drugs Market.

What role do retail pharmacies play in the Dyslipidemia Drugs Market?

Retail pharmacies are expected to be a highly attractive segment within the Dyslipidemia Drugs Market.

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

Dyslipidemia Drugs Market to Expand at a Healthy Cagr of 3.5% From 2019 to 2027

Published by TMR Research Insights

Posted on August 30, 2021

5 min read

Last updated: February 14, 2026

Add as preferred source on Google

Automation in financial services enabling a 360-degree view for customer engagement - Global Banking & Finance Review — This image illustrates the impact of automation in financial services for creating a comprehensive 360-degree view of customer interactions, crucial for enhancing service delivery and operational efficiency.

Dyslipidemia Drugs Market Projected to Grow at 3.5% CAGR by 2027

Transparency Market Research (TMR) has published a new report titled, “Dyslipidemia Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”. According to the report, the global dyslipidemia drugs market was valued at US$ 11.8 Bn in 2018 and is projected to expand at a CAGR of 3.5% from 2019 to 2027. Rising disease awareness through promotional activities, and increasing prevalence of population with cholesterol and triglyceride abnormalities to drive the global dyslipidemia drugs market from 2019 to 2027.

Overview

North America market is the prime contributor to the dyslipidemia drugs market owing to favorable government approval policies coupled with increasing incidence of dyslipidemia in North American countries such as the U.S. and Canada.

For instance, according to the Centers for Disease Control and Prevention (CDC), around 95 million adults in the U.S. (55% of the total population) have total cholesterol levels higher than 200 mg/dL as of 2016. Furthermore, an estimated 29 million adult in U.S. have total cholesterol levels higher than 240 mg/dL.

The organization also stated that the prevalence of dyslipidemia is rapidly increasing among the patient population in the U.S. Additionally, rising obese and diabetic population in the U.S. and Canada further augments the dyslipidemia cases.

Thus, the large population base suffering is expected to drive the global dyslipidemia drugs market during the forecast period.

Rising disease awareness through promotional activities

Several private and government organizations and key companies are actively engaged in increasing awareness about dyslipidemia through organizing various awareness campaigns or publishing guidelines for the same.

For instance, the National Lipid Association introduced “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia”, aiming to provide guidelines for dyslipidemia patients related to cholesterol lowering drug therapy.

In October 2013, Pfizer, Inc. organized Dyslipidemia Awareness and Treatment program in collaboration with the International Atherosclerosis Society. The primary objective of this event was to improve treatment care for cardiovascular patients, particularly focused on dyslipidemia. These programs would increase awareness about dyslipidemia conditions among the patient population, leading to market growth.

Statins Segment to Dominate Market

In terms of drug class, the global dyslipidemia drugs market has been bifurcated into statins, bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacins, and others

The statins segment is expected to dominate the global dyslipidemia drugs market during the forecast period due to the availability or high sale of blockbuster drugs such as Lipitor and Crestor.

Additionally, positive clinical studies coupled with increasing preference of patients to use omega-3 fatty acid derivatives stimulates the growth of the fibric acid and omega-3 fatty acid derivatives segment.

Retail Pharmacies to be Highly Attractive Segment

In terms of distribution channel, the global dyslipidemia drugs market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies

The retail pharmacies segment is likely to dominate the global dyslipidemia drugs market during the forecast period due to increase in the sales of dyslipidemia drugs through retail channels.

Asia Pacific Market to Expand Significantly

In terms of revenue, North America is projected to dominate the global dyslipidemia drugs market from 2019 to 2027. The dominance of this region is majorly attributed to favorable government policies and rising prevalence of dyslipidemia.

Europe is estimated to be the second most attractive market for the dyslipidemia drugs market during the forecast period. Growth in the region is attributed to the conducive environment for growth of pharmaceutical manufacturers due to consumer affordability for branded formulations.

Competitive Landscape in Global Dyslipidemia Drugs Market

The report also provides profiles of leading players operating in the global dyslipidemia drugs market. These include Shionogi & Co., Ltd., Pfizer, Inc., Merck & Co., Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Mylan N.V., Amgen, Inc., AstraZeneca plc, and Abbott Laboratories.

More Trending Reports by Transparency Market Research –

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Dyslipidemia Drugs Market to Expand at a Healthy Cagr of 3.5% From 2019 to 2027

Dyslipidemia Drugs Market Projected to Grow at 3.5% CAGR by 2027

Frequently Asked Questions about Dyslipidemia Drugs Market to Expand at a Healthy CAGR Of 3.5% from 2019 to 2027